{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:17:49Z","timestamp":1790835469161,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Mild cognitive impairment (MCI) may evolve into dementia. Early recognition of possible evolution to Alzheimer's disease (AD) and dementia with Lewy Bodies (DLB) is of importance, but actual diagnostic criteria have some limitations. In this systematic review and meta-analysis, we aimed to find the most accurate markers that can discriminate patients with DLB versus AD, in MCI stage.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We searched several databases up to 17 August 2023 including studies comparing markers that may distinguish DLB-MCI from AD-MCI. We reported data regarding sensitivity, specificity, and the area under the curves (AUCs) with their 95% confidence intervals (CIs).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among 2219 articles initially screened, eight case\u2013control studies and one cohort study were included for a total of 832 outpatients with MCI. The accuracy of cerebrospinal fluid (CSF) markers was the highest among the markers considered (AUC\u2009&gt;\u20090.90 for the CSF markers), with the AUC of CSF A\u03b242\/A\u03b240 of 0.94. The accuracy for clinical symptom scales was very good (AUC\u2009=\u20090.93), as evaluated in three studies. Although limited to one study, the accuracy of FDG-PET (cingulate island sign ratio) was very good (AUC\u2009=\u20090.95) in discriminating DLB from AD in MCI, while the accuracy of SPECT markers and EEG frequencies was variable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Few studies have assessed the accuracy of biomarkers and clinical tools to distinguish DLB from AD at the MCI stage. While results are promising for CSF markers, FDG-PET and clinical symptoms scales, more studies, particularly with a prospective design, are needed to evaluate their accuracy and clinical usefulness.<\/jats:p>\n                <jats:p><jats:bold>Clinical trial registration<\/jats:bold>: Prospero (CRD42023422600).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40520-024-02704-y","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T05:01:27Z","timestamp":1709787687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Markers for the detection of Lewy body disease versus Alzheimer\u2019s disease in mild cognitive impairment: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"36","author":[{"given":"Marianna Ilarj","family":"Burgio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Sar\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Saccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Masnata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giusy","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Catania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Catanese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ligia Juliana","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Vernuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"2704_CR1","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2174\/156720509788929282","volume":"6","author":"M Farlow","year":"2009","unstructured":"Farlow M (2009) Treatment of mild cognitive impairment (MCI). Curr Alzheimer Res 6:362\u2013367","journal-title":"Curr Alzheimer Res"},{"key":"2704_CR2","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.neurobiolaging.2017.01.017","volume":"53","author":"WD Brenowitz","year":"2017","unstructured":"Brenowitz WD, Keene CD, Hawes SE et al (2017) Alzheimer\u2019s disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic-and community-based samples. Neurobiol Aging 53:83\u201392","journal-title":"Neurobiol Aging"},{"key":"2704_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13195-018-0350-6","volume":"10","author":"JPM Kane","year":"2018","unstructured":"Kane JPM, Surendranathan A, Bentley A et al (2018) Clinical prevalence of Lewy body dementia. Alzheimers Res Ther 10:19","journal-title":"Alzheimers Res Ther"},{"key":"2704_CR4","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1002\/mds.20535","volume":"20","author":"F Geser","year":"2005","unstructured":"Geser F, Wenning GK, Poewe W et al (2005) How to diagnose dementia with Lewy bodies: state of the art. Mov Disord: official J Mov Disord Soc 20:S11\u2013S20","journal-title":"Mov Disord: official J Mov Disord Soc"},{"key":"2704_CR5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.arr.2019.01.005","volume":"50","author":"C Mueller","year":"2019","unstructured":"Mueller C, Soysal P, Rongve A et al (2019) Survival time and differences between dementia with Lewy bodies and Alzheimer\u2019s disease following diagnosis: a meta-analysis of longitudinal studies. Ageing Res Rev 50:72\u201380","journal-title":"Ageing Res Rev"},{"key":"2704_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1517\/14656566.2014.936848","volume":"15","author":"M Broadstock","year":"2014","unstructured":"Broadstock M, Ballard C, Corbett A (2014) Latest treatment options for Alzheimer\u2019s disease, Parkinson\u2019s disease dementia and dementia with Lewy bodies. Expert Opin Pharmacother 15:1797\u20131810","journal-title":"Expert Opin Pharmacother"},{"key":"2704_CR7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1212\/WNL.0000000000004058","volume":"89","author":"IG McKeith","year":"2017","unstructured":"McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 89:88\u2013100","journal-title":"Neurology"},{"key":"2704_CR8","doi-asserted-by":"publisher","first-page":"W65","DOI":"10.7326\/0003-4819-151-4-200908180-00136","volume":"151","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151:W65\u2013W94","journal-title":"Ann Intern Med"},{"key":"2704_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg 88:105906","journal-title":"Int J Surg"},{"key":"2704_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","volume":"155","author":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group* Q-","year":"2011","unstructured":"Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group* Q- (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529\u2013536","journal-title":"Ann Intern Med"},{"key":"2704_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/pst.2068","volume":"20","author":"C Luchini","year":"2021","unstructured":"Luchini C, Veronese N, Nottegar A et al (2021) Assessing the quality of studies in meta-research: review\/guidelines on the most important quality assessment tools. Pharm Stat 20:185\u2013195","journal-title":"Pharm Stat"},{"key":"2704_CR12","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1002\/jrsm.12","volume":"1","author":"M Borenstein","year":"2010","unstructured":"Borenstein M, Hedges LV, Higgins JP et al (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synthesis Methods 1:97\u2013111","journal-title":"Res Synthesis Methods"},{"key":"2704_CR13","first-page":"519","volume":"3","author":"CX Ling","year":"2003","unstructured":"Ling CX, Huang J, Zhang H et al (2003) AUC: a statistically consistent and more discriminating measure than accuracy. Ijcai 3:519\u2013524","journal-title":"Ijcaipp"},{"key":"2704_CR14","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539\u20131558","journal-title":"Stat Med"},{"key":"2704_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/biom.12817","volume":"74","author":"L Lin","year":"2018","unstructured":"Lin L, Chu H (2018) Quantifying publication bias in meta-analysis. Biometrics 74:785\u2013794","journal-title":"Biometrics"},{"key":"2704_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1136\/jnnp-2017-316385","volume":"89","author":"O Bousiges","year":"2018","unstructured":"Bousiges O, Bombois S, Schraen S et al (2018) Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer\u2019s disease at the prodromal stage. J Neurol Neurosurg Psychiatry 89:467\u2013475","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2704_CR17","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3233\/JAD-150731","volume":"51","author":"O Bousiges","year":"2016","unstructured":"Bousiges O, Cretin B, Lavaux T et al (2016) Diagnostic value of cerebrospinal fluid biomarkers (Phospho-Tau 181, total-Tau, A\u03b2 42, and A\u03b2 40) in prodromal stage of Alzheimer\u2019s disease and dementia with Lewy bodies. J Alzheimers Dis 51:1069\u20131083","journal-title":"J Alzheimers Dis"},{"key":"2704_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00684-5","volume":"12","author":"O Bousiges","year":"2020","unstructured":"Bousiges O, Philippi N, Lavaux T et al (2020) Differential diagnostic value of total alpha-synuclein assay in the cerebrospinal fluid between Alzheimer\u2019s disease and dementia with Lewy bodies from the prodromal stage. Alzheimers Res Therapy 12:1\u201312","journal-title":"Alzheimers Res Therapy"},{"key":"2704_CR19","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.neulet.2018.07.040","volume":"683","author":"Y Chiba","year":"2018","unstructured":"Chiba Y, Fujishiro H, Iseki E et al (2018) The cingulate island sign in patients with dementia with Lewy bodies or Alzheimer\u2019s disease: a direct comparison between 18 F-FDG PET and 123 I-IMP spect. Neurosci Lett 683:168\u2013173","journal-title":"Neurosci Lett"},{"key":"2704_CR20","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/gps.4742","volume":"32","author":"PC Donaghy","year":"2017","unstructured":"Donaghy PC, Barnett N, Olsen K et al (2017) Symptoms associated with Lewy body disease in mild cognitive impairment. Int J Geriatr Psychiatry 32:1163\u20131171","journal-title":"Int J Geriatr Psychiatry"},{"key":"2704_CR21","first-page":"316","volume":"1","author":"JE Galvin","year":"2015","unstructured":"Galvin JE (2015) Improving the clinical detection of Lewy body dementia with the Lewy body composite risk score. Alzheimers Dement: Diagnosis, Assess Dis Monitoring 1:316\u2013324","journal-title":"Alzheimers Dement: Diagnosis, Assess Dis Monitoring"},{"key":"2704_CR22","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1192\/bjp.2020.234","volume":"218","author":"G Roberts","year":"2021","unstructured":"Roberts G, Donaghy PC, Lloyd J et al (2021) Accuracy of dopaminergic imaging as a biomarker for mild cognitive impairment with Lewy bodies. Br J Psychiatry 218:276\u2013282","journal-title":"Br J Psychiatry"},{"key":"2704_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00650-1","volume":"12","author":"J Schumacher","year":"2020","unstructured":"Schumacher J, Taylor J-P, Hamilton CA et al (2020) Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies. Alzheimers Res Therapy 12:1\u201312","journal-title":"Alzheimers Res Therapy"},{"key":"2704_CR24","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1111\/ene.15783","volume":"30","author":"PC Donaghy","year":"2023","unstructured":"Donaghy PC, Hamilton C, Durcan R et al (2023) Clinical symptoms in mild cognitive impairment with Lewy bodies: frequency, time of onset, and discriminant ability. Eur J Neurol 30:1585\u20131593","journal-title":"Eur J Neurol"},{"key":"2704_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13195-020-00613-6","volume":"12","author":"J Schumacher","year":"2020","unstructured":"Schumacher J, Thomas AJ, Peraza LR et al (2020) EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer\u2019s disease. Alzheimers Res Therapy 12:1\u201312","journal-title":"Alzheimers Res Therapy"},{"key":"2704_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1474-4422(17)30074-1","volume":"16","author":"C Mueller","year":"2017","unstructured":"Mueller C, Ballard C, Corbett A et al (2017) The prognosis of dementia with Lewy bodies. Lancet Neurol 16:390\u2013398","journal-title":"Lancet Neurol"},{"key":"2704_CR27","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1212\/01.WNL.0000138500.73671.DC","volume":"63","author":"H Kaufmann","year":"2004","unstructured":"Kaufmann H, Nahm K, Purohit D et al (2004) Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies. Neurology 63:1093\u20131095","journal-title":"Neurology"},{"key":"2704_CR28","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/WAD.0b013e3181c72b5d","volume":"24","author":"JE Galvin","year":"2010","unstructured":"Galvin JE, Duda JE, Kaufer DI et al (2010) Lewy body dementia: caregiver burden and unmet needs. Alzheimer Dis Assoc Disord 24:177","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2704_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt251","volume":"6","author":"YR Zweig","year":"2014","unstructured":"Zweig YR, Galvin JE (2014) Lewy body dementia: the impact on patients and caregivers. Alzheimers Res Therapy 6:1\u20137","journal-title":"Alzheimers Res Therapy"},{"key":"2704_CR30","first-page":"1127","volume":"115","author":"K Sakai","year":"2013","unstructured":"Sakai K, Yamane Y, Yamamoto Y et al (2013) Depression in dementia with Lewy bodies. Seishin Shinkeigaku Zasshi Psychiatria Neurol Japonica 115:1127\u20131134","journal-title":"Seishin Shinkeigaku Zasshi Psychiatria Neurol Japonica"},{"key":"2704_CR31","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.parkreldis.2021.07.029","volume":"90","author":"MJ Armstrong","year":"2021","unstructured":"Armstrong MJ, Moore K, Jacobson CE et al (2021) Frequency of suicidal ideation and associated clinical features in Lewy body dementia. Parkinsonism Relat Disord 90:33\u201337","journal-title":"Parkinsonism Relat Disord"},{"key":"2704_CR32","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1212\/WNL.0000000000009323","volume":"94","author":"IG McKeith","year":"2020","unstructured":"McKeith IG, Ferman TJ, Thomas AJ et al (2020) Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology 94:743\u2013755","journal-title":"Neurology"},{"key":"2704_CR33","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00702-006-0537-z","volume":"113","author":"M Bibl","year":"2006","unstructured":"Bibl M, Mollenhauer B, Esselmann H et al (2006) CSF diagnosis of Alzheimer\u2019s disease and dementia with Lewy bodies. J Neural Transm 113:1771\u20131778","journal-title":"J Neural Transm"},{"key":"2704_CR34","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1111\/j.1471-4159.2006.04404.x","volume":"101","author":"J Wiltfang","year":"2007","unstructured":"Wiltfang J, Esselmann H, Bibl M et al (2007) Amyloid \u03b2 peptide ratio 42\/40 but not A\u03b242 correlates with phospho-Tau in patients with low-and high-CSF A\u03b240 load. J Neurochem 101:1053\u20131059","journal-title":"J Neurochem"},{"key":"2704_CR35","doi-asserted-by":"publisher","first-page":"759","DOI":"10.3233\/JAD-130107","volume":"36","author":"S Slaets","year":"2013","unstructured":"Slaets S, Le Bastard N, Martin J-J et al (2013) Cerebrospinal fluid A\u03b2 1\u201340 improves differential dementia diagnosis in patients with intermediate P-tau 181P levels. J Alzheimers Dis 36:759\u2013767","journal-title":"J Alzheimers Dis"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-024-02704-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-024-02704-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T05:10:34Z","timestamp":1709788234000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-024-02704-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2704"],"URL":"https:\/\/doi.org\/10.1007\/s40520-024-02704-y","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]},"assertion":[{"value":"29 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"60"}}